Lilly Korea, Handok to copromote Cialis

Published: 2010-07-14 06:57:00

Updated: 2010-07-14 06:57:00

Lilly Korea and Handok Pharm announced on July 12 that they entered into a letter of intent to comarket Cialis (tadalafil) in the domestic impotence market, following their strategic alliances over Cymbalta.

Cialis, an oral treatment for erectile dysfunction, is a selective inhibitor of cyclic...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK